

Personalis, Inc. (PSNL)

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0001527753

Personalis, Inc.

PSNL; healthcare

Grade

D/E

on the D/E boundary of 371 graded peers
percentile 81.9; sampling error 2.5 points; lower is stronger

Rank

304 of 371

Profitability

D/E

percentile 79.0

Solvency

C

percentile 47.4

Growth and financing

C

percentile 55.4

Reliability

0.87 AUC
filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025

Peer failure rate

1.03% a year
Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

\$120M to \$591M assets
total assets \$334.2M

Standard universe

inside
revenue above \$1M and assets above \$10M

Warnings

none active
not computable: fortress balance sheet

Inputs computable

10 of 14

Graded from

filings received through Feb 26, 2026
225 days before the rescan; latest periodic filing 10-Q received Aug 4, 2026

Last close

\$16.05
2026-10-08; market equity \$1.7B

Price used in grade

None



D/E, the sloth

on the D/E boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: E from Mar 21, 2024, D from Mar 21, 2025, E from Mar 21, 2026, D/E from Sep 2

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. Our testing services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and clinical trials. We also provide whole exome sequencing services for other diagnostic companies

and whole genome sequencing services for population sequencing initiatives.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 79.0						
Gross profitability		4.7%	32.2%	85.2	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(2.1%)	(6.6%)	76.3	811	2025-12-31
Gross margin stability, five years		6.1 pts	2.8 pts	75.6	243	2025-12-31
Solvency, sleeve percentile 47.4						
Twelve-month failure probability		0.04%	0.07%	27.1	248	2026-06-30
Altman Z double-prime		0.31	(0.31)	35.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		(429.55x)	(4.51x)	100.0	81	2025-12-31
Current ratio		6.76x	2.96x	26.7	839	2025-12-31
Growth and financing, sleeve percentile 55.4						
Revenue growth, three-year compound		2.3%	10.0%	65.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		4.5%	2.1%	42.1	704	2025-12-31
Net share issuance, one year		18.5%	2.5%	58.8	634	2026-02-20

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
299	Lucid Diagnostics Inc. (LUCD)	80.5	D/E	dilution
300	Merck & Co., Inc. (MRK)	80.8	D/E	

301	Lexicon Pharmaceuticals, Inc. (LXR)	81.1	D/E	fortress balance sheet
302	Hyperfine, Inc. (HYPR)	81.4	D/E	
303	Surgery Partners, Inc. (SGRY)	81.6	D/E	late filer
304	Personalis, Inc. (PSNL) <	81.9	D/E	
305	Accuray Inc. (ARAY)	82.2	D/E	late filer
306	Moderna, Inc. (MRNA)	82.4	D/E	
307	Stereotaxis, Inc. (STXS)	82.7	E	
308	SkinHealth Systems Inc. (SKIN)	83.0	E	
309	Karyopharm Therapeutics Inc. (KPTI)	83.2	E	dilution, distress, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	157.4%	8.0%	94
Distance from 52-week high	(12.6%)	(31.4%)	78
EBIT to enterprise value	(5.4%)	(1.5%)	41
Free cash flow yield	(4.6%)	(1.0%)	41
Book value to price	0.14	0.28	33
Sales to price	0.04	0.31	15
Composite equity issuance, five years	89.4%	20.3%	76
Relative strength against the sector, log excess return	0.73	(0.14)	94

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$94.0M
Operating cash flow, four quarters	-\$92.3M
Months of runway	12.2
Days since last periodic filing	66 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	\$39.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$69.6M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
2	cost of revenue	us-gaap:CostOfRevenue	\$53.9M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
3	assets	us-gaap:Assets	\$334.2M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
4	net income	us-gaap:NetIncomeLoss	-\$81.3M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$74.9M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
6	assets	us-gaap:Assets	\$270.3M	2024-12-31	2026-02-26	10-K	0001193125-26-076615
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$84.6M	2024-12-31	2026-02-26	10-K	0001193125-26-076615
8	cost of revenue	us-gaap:CostOfRevenue	\$57.8M	2024-12-31	2026-02-26	10-K	0001193125-26-076615

9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$73.5M	2023-12-31	2025-02-27	10-K	0000950170-25-029221
10	cost of revenue	us-gaap:CostOfRevenue	\$55.3M	2023-12-31	2025-02-27	10-K	0000950170-25-029221
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$65.0M	2022-12-31	2024-02-28	10-K	0000950170-24-022097
12	cost of revenue	us-gaap:CostOfRevenue	\$51.7M	2022-12-31	2024-02-28	10-K	0000950170-24-022097
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$85.5M	2021-12-31	2024-02-28	10-K	0000950170-24-022097
14	cost of revenue	us-gaap:CostOfRevenue	\$53.8M	2021-12-31	2024-02-28	10-K	0000950170-24-022097
15	current assets	us-gaap:AssetsCurrent	\$268.0M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
16	current liabilities	us-gaap:LiabilitiesCurrent	\$39.6M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$631.3M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
18	operating income	us-gaap:OperatingIncomeLoss	-\$88.1M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
19	book equity	us-gaap:StockholdersEquity	\$261.2M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
20	liabilities	us-gaap:Liabilities	\$73.0M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
21	interest expense	us-gaap:InterestExpense	\$205,000	2025-12-31	2026-02-26	10-K	0001193125-26-076615
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.5M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$45.1M	2024-12-31	2026-02-26	10-K	0001193125-26-076615
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.6M	2024-12-31	2026-02-26	10-K	0001193125-26-076615
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$56.3M	2023-12-31	2025-02-27	10-K	0000950170-25-029221
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$10.9M	2023-12-31	2025-02-27	10-K	0000950170-25-029221
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$70.2M	2022-12-31	2024-02-28	10-K	0000950170-24-022097
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$49.9M	2022-12-31	2024-02-28	10-K	0000950170-24-022097
29	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$10.0M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$11.2M	2025-12-31	2026-02-26	10-K	0001193125-26-076615
31	income tax	us-gaap:IncomeTaxExpenseBenefit	\$21,000	2025-12-31	2026-02-26	10-K	0001193125-26-076615
32	current assets	us-gaap:AssetsCurrent	\$203.0M	2024-12-31	2026-02-26	10-K	0001193125-26-076615
33	current liabilities	us-gaap:LiabilitiesCurrent	\$31.1M	2024-12-31	2026-02-26	10-K	0001193125-26-076615
34	assets	us-gaap:Assets	\$225.1M	2023-12-31	2025-02-27	10-K	0000950170-25-029221
35	assets	us-gaap:Assets	\$292.7M	2022-12-31	2024-02-28	10-K	0000950170-24-022097
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	104,631,832	2026-02-20	2026-02-26	10-K	0001193125-26-076615
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,263,269	2025-02-21	2025-02-27	10-K	0000950170-25-029221